BR112021017310A8 - Método para produzir vacina fracionada de ha de influenza - Google Patents

Método para produzir vacina fracionada de ha de influenza

Info

Publication number
BR112021017310A8
BR112021017310A8 BR112021017310A BR112021017310A BR112021017310A8 BR 112021017310 A8 BR112021017310 A8 BR 112021017310A8 BR 112021017310 A BR112021017310 A BR 112021017310A BR 112021017310 A BR112021017310 A BR 112021017310A BR 112021017310 A8 BR112021017310 A8 BR 112021017310A8
Authority
BR
Brazil
Prior art keywords
influenza
vaccine
fractioned
fractionated
stem region
Prior art date
Application number
BR112021017310A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112021017310A2 (https=
Inventor
Takahashi Yoshimasa
Adachi Yu
Ato Manabu
Original Assignee
Japan As Represented By The Director General Of Nat Institute Of Infectious Diseases
Sumitomo Dainippon Pharma Co Ltd
Sumitomo Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan As Represented By The Director General Of Nat Institute Of Infectious Diseases, Sumitomo Dainippon Pharma Co Ltd, Sumitomo Pharma Co Ltd filed Critical Japan As Represented By The Director General Of Nat Institute Of Infectious Diseases
Publication of BR112021017310A2 publication Critical patent/BR112021017310A2/pt
Publication of BR112021017310A8 publication Critical patent/BR112021017310A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
BR112021017310A 2019-03-04 2020-03-03 Método para produzir vacina fracionada de ha de influenza BR112021017310A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019038662 2019-03-04
PCT/JP2020/008974 WO2020179797A1 (ja) 2019-03-04 2020-03-03 インフルエンザｈａスプリットワクチンの製造方法

Publications (2)

Publication Number Publication Date
BR112021017310A2 BR112021017310A2 (https=) 2021-11-16
BR112021017310A8 true BR112021017310A8 (pt) 2022-12-06

Family

ID=72337458

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021017310A BR112021017310A8 (pt) 2019-03-04 2020-03-03 Método para produzir vacina fracionada de ha de influenza

Country Status (15)

Country Link
US (1) US12491240B2 (https=)
EP (1) EP3936147A4 (https=)
JP (1) JP7545955B2 (https=)
KR (1) KR20210135261A (https=)
CN (1) CN114096273B (https=)
AU (1) AU2020233456B2 (https=)
BR (1) BR112021017310A8 (https=)
CA (1) CA3132578A1 (https=)
EA (1) EA202192398A1 (https=)
IL (1) IL285984A (https=)
MX (1) MX2021010685A (https=)
MY (1) MY208974A (https=)
PH (1) PH12021552094A1 (https=)
SG (1) SG11202109566XA (https=)
WO (1) WO2020179797A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3107409A1 (en) 2018-07-23 2020-01-30 Japan As Represented By Director General Of National Institute Of Infectious Diseases Composition containing influenza vaccine
MX2022005513A (es) * 2019-11-07 2022-06-08 Seqirus Uk Ltd Composiciones y metodos para producir una vacuna viral con tama?o de particula reducido.
EP4703377A1 (en) 2023-04-26 2026-03-04 Japan Institute for Health Security Anti-influenza antibody

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2374894B1 (en) * 1993-09-13 2014-09-17 Protein Sciences Corporation A method for producing influenza hemagglutinin multivalent vaccines
US8278083B2 (en) 2004-03-22 2012-10-02 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Inactivated influenza virus compositions
US20230201329A1 (en) * 2006-07-17 2023-06-29 Glaxosmithkline Biologicals Sa Influenza vaccine
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
WO2008114819A1 (ja) 2007-03-20 2008-09-25 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
US9452209B2 (en) * 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
WO2009115917A2 (en) * 2008-03-18 2009-09-24 Novartis Ag Improvements in preparation of influenza virus vaccine antigens
WO2010010467A2 (en) 2008-07-25 2010-01-28 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
WO2010047509A2 (ko) 2008-10-24 2010-04-29 아주대학교 산학협력단 친화도와 안정성이 향상된 항 ｄｒ5 항체, 및 이를 포함하는 암 예방 또는 치료용 조성물
US8815252B2 (en) * 2008-11-25 2014-08-26 Baxter Healthcare Sa Method for production of pH stable enveloped viruses
CN101524538A (zh) 2009-03-26 2009-09-09 成都康华生物制品有限公司 一种流感-大流行流感二价联合疫苗及其制备方法
CA2790380A1 (en) 2010-02-18 2011-08-25 Mount Sinai School Of Medicine Vaccines for use in the prophylaxis and treatment of influenza virus disease
WO2011111966A2 (en) 2010-03-08 2011-09-15 Celltrion, Inc. Human monoclonal antibodies derived from human b cells and having neutralizing activity against influenza a viruses
EP3248615A1 (en) 2010-03-30 2017-11-29 Mount Sinai School of Medicine of New York University Influenza virus vaccines and uses thereof
CN103502263A (zh) 2011-04-21 2014-01-08 巴克斯特国际公司 用于从疫苗离析和量化抗原的方法
CN102406931B (zh) * 2011-11-25 2014-02-05 成都康华生物制品有限公司 大流行流感病毒裂解疫苗
CN104302317B (zh) 2012-05-16 2016-07-06 Kj生物科学有限公司 新型和改进的流感疫苗
KR20140118682A (ko) 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
CN106794241A (zh) 2014-08-18 2017-05-31 圣诺菲·帕斯图尔公司 烷基化流感疫苗
SG11201705264WA (en) 2014-12-31 2017-07-28 The Usa As Represented By The Secretary Detp Of Health And Human Services Novel multivalent nanoparticle-based vaccines
JP2018517405A (ja) * 2015-05-04 2018-07-05 エピバックス インコーポレーテッド インフルエンザａ／上海／２／２０１３ ｈ７配列の改変ｈ７赤血球凝集素糖タンパク質
ES2805724T3 (es) * 2015-09-29 2021-02-15 Sumitomo Dainippon Pharma Co Ltd Compuestos de adenina conjugados y su uso como adyuvantes de vacunas
PL3603619T3 (pl) * 2017-03-29 2025-11-17 Sumitomo Pharma Co., Ltd. Preparat adjuwantu szczepionkowego
MY204177A (en) * 2017-09-04 2024-08-14 Japan As Represented By Director General Of Nat Institute Of Infectious Diseases Method for producing influenza ha split vaccine
JP7403733B2 (ja) 2017-09-04 2023-12-25 国立感染症研究所長 インフルエンザｈａスプリットワクチンの製造方法
CA3107409A1 (en) * 2018-07-23 2020-01-30 Japan As Represented By Director General Of National Institute Of Infectious Diseases Composition containing influenza vaccine
CN113194986A (zh) * 2018-12-26 2021-07-30 大日本住友制药株式会社 包括疫苗佐剂的制剂
WO2020176524A1 (en) * 2019-02-28 2020-09-03 Novavax, Inc. Methods for preventing disease or disorder caused by rsv infection

Also Published As

Publication number Publication date
CA3132578A1 (en) 2020-09-10
WO2020179797A1 (ja) 2020-09-10
US20220152191A1 (en) 2022-05-19
AU2020233456A1 (en) 2021-10-07
MY208974A (en) 2025-06-14
EP3936147A4 (en) 2022-09-28
MX2021010685A (es) 2021-12-10
EA202192398A1 (ru) 2021-11-23
PH12021552094A1 (en) 2022-05-30
IL285984A (en) 2021-10-31
JPWO2020179797A1 (https=) 2020-09-10
CN114096273A (zh) 2022-02-25
JP7545955B2 (ja) 2024-09-05
BR112021017310A2 (https=) 2021-11-16
KR20210135261A (ko) 2021-11-12
AU2020233456B2 (en) 2026-04-09
US12491240B2 (en) 2025-12-09
SG11202109566XA (en) 2021-10-28
CN114096273B (zh) 2026-03-17
EP3936147A1 (en) 2022-01-12

Similar Documents

Publication Publication Date Title
BR112021017310A8 (pt) Método para produzir vacina fracionada de ha de influenza
MX2022000733A (es) Derivados cannabinoides como compuestos farmaceuticamente activos y metodos de preparacion de los mismos.
CO2021005987A2 (es) Compuestos de anillo fusionado
PH12020500414A1 (en) Method for producing influenza ha split vaccine
CL2017001638A1 (es) Productos farmacéuticos y composiciones líquidas estables de anticuerpos contra il-17
BR112016005270A2 (pt) compostos de aza-piridona, composições farmacêuticas e seus usos
CO2020001927A2 (es) Método de producción de composiciones farmacéuticas que comprende el virus chikungunya inmunogénico chikv-delta5nsp3
CL2019001200A1 (es) Vacuna contra el parvovirus porcino y el virus del síndrome respiratorio reproductivo porcino y métodos de producción de esta.
MX2018003569A (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
BR112019025548A2 (pt) Inibição ou redução do crescimento de plantas por biocimentação
MX2021010060A (es) Produccion de virus en huevos aviares.
EA201990010A1 (ru) Вакцина против вируса инфекционного бронхита
MX2019013816A (es) Compuesto usado como regulador de la autofagia, metodo de preparacion y sus usos.
BR112016026164A2 (pt) novo microrganismo e método para a produção de 1,2-propanodiol com base em acetol redutase dependente de nadph e suprimento de nadph aprimorado
MX2025004075A (es) Vacunas para circovirus porcino tipo 3 (pcv3), y produccion y sus usos
BR112021001188A8 (pt) Composição que contém vacina contra a influenza
UY38895A (es) PROCESO PARA PREPARAR (15a,16a,17ß)-ESTRA-1,3,5(10)-TRIENO-3,15,16,17-TETROL (ESTETROL) E INTERMEDIOS DE DICHO PROCESO
BR112019005886A2 (pt) tratamento com água de material lipídico
BR112015032100B8 (pt) Processo para a geração de um radioisótopo
MX2022006320A (es) Composicion para la inhibicion de la produccion de hmf que comprende disacarido de alulosa.
CO2020000021A2 (es) Método para preparar reserva de cepas víricas de trabajo para la influenza, método para preparar la vacuna contra la influenza usando la misma reserva de cepas, y la reserva de cepas víricas preparadas por el mismo método
BR112022008286A2 (pt) Compostos transportadores de hidrogênio
BR112017005134A2 (pt) tratamento e cura funcional de infecção por hiv por anticorpos monoclonais para inibição de entrada de hiv competitiva mediada por cd
MX2021007267A (es) Agente para mejorar la tolerancia al calor o la tolerancia a sal de plantas.
MX2017013879A (es) Composiciones que comprenden anakinra.

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: JAPAN AS REPRESENTED BY THE DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES (JP) ; SUMITOMO PHARMA CO., LTD. (JP)

B25G Requested change of headquarter approved

Owner name: JAPAN AS REPRESENTED BY THE DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES (JP) ; SUMITOMO PHARMA CO., LTD. (JP)